AU2018356944A1 - Novel T-cell receptor - Google Patents

Novel T-cell receptor Download PDF

Info

Publication number
AU2018356944A1
AU2018356944A1 AU2018356944A AU2018356944A AU2018356944A1 AU 2018356944 A1 AU2018356944 A1 AU 2018356944A1 AU 2018356944 A AU2018356944 A AU 2018356944A AU 2018356944 A AU2018356944 A AU 2018356944A AU 2018356944 A1 AU2018356944 A1 AU 2018356944A1
Authority
AU
Australia
Prior art keywords
tcr
cell
clone
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018356944A
Other languages
English (en)
Inventor
Garry DOLTON
Andrew Sewell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Publication of AU2018356944A1 publication Critical patent/AU2018356944A1/en
Priority to AU2024202735A priority Critical patent/AU2024202735A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018356944A 2017-10-26 2018-10-22 Novel T-cell receptor Abandoned AU2018356944A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202735A AU2024202735A1 (en) 2017-10-26 2024-04-26 Novel T-cell receptor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1717578.7A GB201717578D0 (en) 2017-10-26 2017-10-26 Novel T-cell receptor
GB1717578.7 2017-10-26
GB1806155.6 2018-04-16
GBGB1806155.6A GB201806155D0 (en) 2017-10-26 2018-04-16 Novel t-cell receptor
PCT/GB2018/053045 WO2019081902A1 (en) 2017-10-26 2018-10-22 NEW LYMPHOCYTE RECEPTOR T

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202735A Division AU2024202735A1 (en) 2017-10-26 2024-04-26 Novel T-cell receptor

Publications (1)

Publication Number Publication Date
AU2018356944A1 true AU2018356944A1 (en) 2020-04-16

Family

ID=60580240

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018356944A Abandoned AU2018356944A1 (en) 2017-10-26 2018-10-22 Novel T-cell receptor
AU2024202735A Abandoned AU2024202735A1 (en) 2017-10-26 2024-04-26 Novel T-cell receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202735A Abandoned AU2024202735A1 (en) 2017-10-26 2024-04-26 Novel T-cell receptor

Country Status (17)

Country Link
US (2) US11725039B2 (enExample)
EP (2) EP4039700A1 (enExample)
JP (1) JP7289311B2 (enExample)
KR (1) KR20200078497A (enExample)
CN (1) CN111278855B (enExample)
AU (2) AU2018356944A1 (enExample)
BR (1) BR112020007880A2 (enExample)
CA (1) CA3077635A1 (enExample)
DK (1) DK3700925T3 (enExample)
EA (1) EA202091015A1 (enExample)
ES (1) ES2907819T3 (enExample)
GB (2) GB201717578D0 (enExample)
IL (1) IL274025A (enExample)
MX (1) MX2020004334A (enExample)
PL (1) PL3700925T3 (enExample)
SG (1) SG11202002537WA (enExample)
WO (1) WO2019081902A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
BR112022013633A2 (pt) * 2020-01-09 2022-09-13 Biomunex Pharmaceuticals Anticorpos multiespecíficos que ligam tanto células mait quanto tumorais
CN115943307A (zh) * 2020-01-16 2023-04-07 巴塞尔大学 用于免疫调节的mr1配体和药物组合物
WO2021250511A1 (ko) * 2020-06-10 2021-12-16 주식회사 유틸렉스 Mr1에 결합하는 t-세포 수용체 및 이의 용도
US20230381235A1 (en) * 2020-11-04 2023-11-30 Fate Therapeutics, Inc. Multiplexed engineered ipscs and immune effector cells targeting solid tumors
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
IL309957A (en) 2021-07-14 2024-03-01 2Seventy Bio Inc Engineered t cell receptors fused to binding domains from antibodies
WO2023002204A1 (en) 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
KR20230088292A (ko) * 2021-12-10 2023-06-19 주식회사 유틸렉스 MR1 제한적 Panck T 세포 및 이의 제조방법
WO2023148494A1 (en) 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
KR20250008809A (ko) 2022-04-08 2025-01-15 리제너론 파마슈티칼스 인코포레이티드 다분할 수용체 및 신호전달 복합체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI819228B (zh) * 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
JP6164759B2 (ja) 2013-11-21 2017-07-19 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用
CN110462024B (zh) * 2017-03-07 2024-08-09 巴塞尔大学 用于癌症免疫疗法的mr1限制性t细胞受体
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor

Also Published As

Publication number Publication date
CN111278855A (zh) 2020-06-12
EP4039700A1 (en) 2022-08-10
US11078252B2 (en) 2021-08-03
BR112020007880A2 (pt) 2020-10-27
JP2021500406A (ja) 2021-01-07
CN111278855B (zh) 2024-04-02
GB201717578D0 (en) 2017-12-13
EP3700925B8 (en) 2022-02-16
US20200369742A1 (en) 2020-11-26
ES2907819T3 (es) 2022-04-26
JP7289311B2 (ja) 2023-06-09
EP3700925A1 (en) 2020-09-02
EP3700925B1 (en) 2021-12-29
PL3700925T3 (pl) 2022-05-02
IL274025A (en) 2020-06-30
US11725039B2 (en) 2023-08-15
DK3700925T3 (en) 2022-04-04
SG11202002537WA (en) 2020-05-28
US20210147506A1 (en) 2021-05-20
KR20200078497A (ko) 2020-07-01
MX2020004334A (es) 2020-08-03
GB201806155D0 (en) 2018-05-30
WO2019081902A1 (en) 2019-05-02
AU2024202735A1 (en) 2024-05-30
CA3077635A1 (en) 2019-05-02
EA202091015A1 (ru) 2020-07-17

Similar Documents

Publication Publication Date Title
US11078252B2 (en) T-cell receptor
Klebanoff et al. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
AU2021202223B2 (en) Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
JP7770188B2 (ja) 養子細胞療法のための標的共刺激を提供する受容体
Frankel et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase
AU2018235130B2 (en) Method
CN116731156A (zh) 用于癌症免疫治疗的转染t细胞和t细胞受体
JP2017522859A (ja) グリピカン３に特異的なｔ細胞受容体、及び肝細胞癌の免疫療法のためのその使用
CN111372944A (zh) 新型γδT细胞受体和其配体
US12479903B2 (en) CD5 specific T cell receptor cell or gene therapy
EP4651887A1 (en) T-cell receptors
HK40034405A (en) Novel t-cell receptor
HK40034405B (en) Novel t-cell receptor
EA045252B1 (ru) Новый т-клеточный рецептор
EP4472742A1 (en) Novel t-cell receptor
CN121127488A (zh) 一种t细胞受体及其用途
McGarty CAR-T Cells and Cancer
Wheeler Identifying a novel γδ T-cell stress ligand: Potential for cancer immunotherapy
JP2023550154A (ja) サイトケラチンに対する抗腫瘍応答

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted